Clinical trial shows gene editing works for β-Thalassaemia, too

A clinical trial proved that CRISPR-based gene editing can treat β-Thalassaemia, adding another blood disorder to the list of conditions curable by design. This moves the therapy closer to becoming a standard option rather than a desperate last resort.